Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 11;12(11):3339. doi: 10.3390/cancers12113339

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Inhibition of DNL combined with enzalutamide treatment has a greater impact on proliferation and induced higher cell death in prostate cancer cells than single-agent-based treatments. Proliferation rates and percentage of cell proliferation of PC cell lines LNCaP (A) and C4-2B (B) were assessed using IncuCyte over six days of treatment with either 10 μM enzalutamide (ENZ), 5 μM SCD1 inhibitor (SCD1 INH) or a combination of both (COMBO). Western blot analyses of cleaved PARP proteins from LNCaP (C) and C4-2B cells (D) treated for six days as previously described. Dead cell counts of LNCaP (E) and C4-2B cells (F) analyzed by flow cytometry after six days of treatment with 10 μM ENZ, 5 μM SCD1 INH or COMBO. Data represent the mean ± SD of three independent experiments. Data were analyzed using the one-way ANOVA test. * p < 0.05, ** p < 0.01 and *** p < 0.001.